Tratamiento de la leucemia linfoide aguda del adulto: Experiencia de un hospital en la Ciudad de México

Background: GIMEMA ALL 0288 trial was designed to evaluate the impact of a 7-day prednisone (PDN) pretreatment on complete remission of acute lymphoblastic leukemia. We adopted this trial in 2007. Aim: To evaluate the results of treatment in two cohorts of patients with acute lymphoblastic leukemia,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ramos,Christian, Rozen,Etta, León,María, Martínez T,Adolfo, Olarte,Irma, Catellanos,Humberto, Martínez,Carlos, Montaño,Efreen, Kassack I,Juan, Zamora,Jorge, Miranda,Enrique, De la Ros,Andrés, Gutiérrez,Mario, Collazo,Juan
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2011
Materias:	Daunorubicin Leukemia, lymphoid Prednisone
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872011000900004
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872011000900004
record_format	dspace
spelling	oai:scielo:S0034-988720110009000042011-11-17Tratamiento de la leucemia linfoide aguda del adulto: Experiencia de un hospital en la Ciudad de MéxicoRamos,ChristianRozen,EttaLeón,MaríaMartínez T,AdolfoOlarte,IrmaCatellanos,HumbertoMartínez,CarlosMontaño,EfreenKassack I,JuanZamora,JorgeMiranda,EnriqueDe la Ros,AndrésGutiérrez,MarioCollazo,Juan Daunorubicin Leukemia, lymphoid Prednisone Background: GIMEMA ALL 0288 trial was designed to evaluate the impact of a 7-day prednisone (PDN) pretreatment on complete remission of acute lymphoblastic leukemia. We adopted this trial in 2007. Aim: To evaluate the results of treatment in two cohorts of patients with acute lymphoblastic leukemia, treated from 2007 to January 2009 and from February to December 2009. Material and Methods: We studied 99 patients treated in the first period (58 males) and 54 patients treated in the second period (33 males) The age of patients ranged from 16 to 60 years and 70% of patients were of high risk. BCR/ABL fusion transcript was present in 12% of patients. Results: Remission rates were 61 and 51% for patients of the first and second group of treatment, respectively. The main cause of death were infections during the induction period. There were 49 relapses, mainly detected in the blood marrow. Global and event free 34 months survival were 32 and 30% respectively. Multivariate analysis disclosed risk stratification and central nervous system infiltration as risk factors for mortality. Conclusions: The main obstacles for the treatment of acute lymphoblastic leukemia in these cohorts of patients were the high incidence of infections and the lack of use of growth stimulating factors.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.139 n.9 20112011-09-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872011000900004es10.4067/S0034-98872011000900004
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Daunorubicin Leukemia, lymphoid Prednisone
spellingShingle	Daunorubicin Leukemia, lymphoid Prednisone Ramos,Christian Rozen,Etta León,María Martínez T,Adolfo Olarte,Irma Catellanos,Humberto Martínez,Carlos Montaño,Efreen Kassack I,Juan Zamora,Jorge Miranda,Enrique De la Ros,Andrés Gutiérrez,Mario Collazo,Juan Tratamiento de la leucemia linfoide aguda del adulto: Experiencia de un hospital en la Ciudad de México
description	Background: GIMEMA ALL 0288 trial was designed to evaluate the impact of a 7-day prednisone (PDN) pretreatment on complete remission of acute lymphoblastic leukemia. We adopted this trial in 2007. Aim: To evaluate the results of treatment in two cohorts of patients with acute lymphoblastic leukemia, treated from 2007 to January 2009 and from February to December 2009. Material and Methods: We studied 99 patients treated in the first period (58 males) and 54 patients treated in the second period (33 males) The age of patients ranged from 16 to 60 years and 70% of patients were of high risk. BCR/ABL fusion transcript was present in 12% of patients. Results: Remission rates were 61 and 51% for patients of the first and second group of treatment, respectively. The main cause of death were infections during the induction period. There were 49 relapses, mainly detected in the blood marrow. Global and event free 34 months survival were 32 and 30% respectively. Multivariate analysis disclosed risk stratification and central nervous system infiltration as risk factors for mortality. Conclusions: The main obstacles for the treatment of acute lymphoblastic leukemia in these cohorts of patients were the high incidence of infections and the lack of use of growth stimulating factors.
author	Ramos,Christian Rozen,Etta León,María Martínez T,Adolfo Olarte,Irma Catellanos,Humberto Martínez,Carlos Montaño,Efreen Kassack I,Juan Zamora,Jorge Miranda,Enrique De la Ros,Andrés Gutiérrez,Mario Collazo,Juan
author_facet	Ramos,Christian Rozen,Etta León,María Martínez T,Adolfo Olarte,Irma Catellanos,Humberto Martínez,Carlos Montaño,Efreen Kassack I,Juan Zamora,Jorge Miranda,Enrique De la Ros,Andrés Gutiérrez,Mario Collazo,Juan
author_sort	Ramos,Christian
title	Tratamiento de la leucemia linfoide aguda del adulto: Experiencia de un hospital en la Ciudad de México
title_short	Tratamiento de la leucemia linfoide aguda del adulto: Experiencia de un hospital en la Ciudad de México
title_full	Tratamiento de la leucemia linfoide aguda del adulto: Experiencia de un hospital en la Ciudad de México
title_fullStr	Tratamiento de la leucemia linfoide aguda del adulto: Experiencia de un hospital en la Ciudad de México
title_full_unstemmed	Tratamiento de la leucemia linfoide aguda del adulto: Experiencia de un hospital en la Ciudad de México
title_sort	tratamiento de la leucemia linfoide aguda del adulto: experiencia de un hospital en la ciudad de méxico
publisher	Sociedad Médica de Santiago
publishDate	2011
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872011000900004
work_keys_str_mv	AT ramoschristian tratamientodelaleucemialinfoideagudadeladultoexperienciadeunhospitalenlaciudaddemexico AT rozenetta tratamientodelaleucemialinfoideagudadeladultoexperienciadeunhospitalenlaciudaddemexico AT leonmaria tratamientodelaleucemialinfoideagudadeladultoexperienciadeunhospitalenlaciudaddemexico AT martineztadolfo tratamientodelaleucemialinfoideagudadeladultoexperienciadeunhospitalenlaciudaddemexico AT olarteirma tratamientodelaleucemialinfoideagudadeladultoexperienciadeunhospitalenlaciudaddemexico AT catellanoshumberto tratamientodelaleucemialinfoideagudadeladultoexperienciadeunhospitalenlaciudaddemexico AT martinezcarlos tratamientodelaleucemialinfoideagudadeladultoexperienciadeunhospitalenlaciudaddemexico AT montanoefreen tratamientodelaleucemialinfoideagudadeladultoexperienciadeunhospitalenlaciudaddemexico AT kassackijuan tratamientodelaleucemialinfoideagudadeladultoexperienciadeunhospitalenlaciudaddemexico AT zamorajorge tratamientodelaleucemialinfoideagudadeladultoexperienciadeunhospitalenlaciudaddemexico AT mirandaenrique tratamientodelaleucemialinfoideagudadeladultoexperienciadeunhospitalenlaciudaddemexico AT delarosandres tratamientodelaleucemialinfoideagudadeladultoexperienciadeunhospitalenlaciudaddemexico AT gutierrezmario tratamientodelaleucemialinfoideagudadeladultoexperienciadeunhospitalenlaciudaddemexico AT collazojuan tratamientodelaleucemialinfoideagudadeladultoexperienciadeunhospitalenlaciudaddemexico
_version_	1718436585554313216

Tratamiento de la leucemia linfoide aguda del adulto: Experiencia de un hospital en la Ciudad de México

Ejemplares similares